A sweeping Chinese review argues that the coenzyme NAD+ sits at the metabolic center of all fourteen recognized hallmarks of aging, but its central message is a warning: the era of “blind” NAD+ supplementation is over, because the same molecule that repairs aging cells can also feed cancers and fuel inflammation, demanding a shift to “precision” tissue-specific dosing.
For a decade, NAD+ has been the darling of the longevity-supplement aisle. The logic is seductive: levels of this essential coenzyme fall as we age, so topping it back up — usually with the precursors NMN or NR — ought to wind the clock back. This review, from the China Academy of Chinese Medical Sciences, does something more ambitious and more sobering. It maps NAD+ onto every one of the fourteen “hallmarks of aging,” the field’s current master-list of what actually goes wrong as bodies grow old, from fraying telomeres and failing mitochondria to chronic inflammation, gut dysbiosis, and even the biology of loneliness.
The Big Idea is that NAD+ is not just one more player but the central hub wiring these processes together. The authors trace a recurring loop: damage to the cell (broken DNA, shortened telomeres, misfolded proteins) burns through NAD+ via consuming enzymes called PARPs and CD38; the resulting NAD+ shortage then cripples the sirtuin and repair systems that depend on it, which causes more damage. Aging, in this telling, is partly a slow-motion energy bankruptcy, and NAD+ is the currency.
But the review’s real contribution is its refusal to cheerlead. It dwells on NAD+'s “dark side.” Because cancer cells are metabolically hungry, flooding the body with NAD+ precursors may hand established tumors exactly the fuel they crave. The same molecule can also reinforce the “senescence-associated secretory phenotype” (SASP) — the toxic inflammatory broth that aging cells leak into their surroundings. So more is not always better, and timing and tissue matter enormously.
From this, the authors call for a paradigm shift to “precision NAD+ modulation”: measuring an individual’s cancer risk, inflammatory profile, and tissue-specific metabolism before deciding whether to boost NAD+ synthesis, block its breakdown (for example by inhibiting CD38), or leave it alone. They also highlight an emerging frontier — NAD+ moving between organs packaged inside extracellular vesicles — suggesting aging is a whole-body relay, not just a cell-by-cell decline.
The honest takeaway is that NAD+ biology is richer, and riskier, than the supplement marketing implies. Human trial data remain thin, mixed, and dominated by rare premature-aging diseases rather than normal aging. The promise is real; the certainty is not.
Actionable Insights
The practical, take-home messages — with effect sizes extracted from the primary trials this review cites, since the review itself supplies none:
- NAD+ precursors reliably raise NAD+ but rarely move hard outcomes. Across cited human trials, supplements (NR/NMN, ~250–2000 mg/day) consistently and substantially increase blood NAD+ — one COPD trial reported roughly doubled blood NAD+ — yet downstream clinical endpoints (insulin sensitivity, cognition, muscle function) usually do not change. The honest effect size on the outcomes you care about is frequently near zero.
- The clearest signal is in inflammation, not rejuvenation. A Phase I COPD trial cited here reported NR 2 g/day cut sputum IL-8 by 52.6% — a large within-group anti-inflammatory effect, though uncontrolled and small.
- Best-documented benefits are in rare disease, not healthy aging. In Werner syndrome and ataxia-telangiectasia (premature-aging disorders), NR improved arterial stiffness, skin-ulcer healing, and motor coordination. These are dramatic in sick patients but do not generalize to healthy people.
- Sex and tissue matter. NMN 250 mg/day improved muscle insulin sensitivity in prediabetic women, while NR 2 g/day in obese men changed NAD+ metabolites but not insulin sensitivity.
- The single most actionable instruction is a caution: if you have elevated cancer risk or a high inflammatory/senescent burden, the mechanistic case for restraint — not enthusiasm — is real. “Clear senescent cells first, replenish NAD+ second” is the review’s recommended sequence.
Source:
-
Paywalled Paper: NAD⁺ as a central metabolic hub Regulating the hallmarks of aging:
Mechanisms and therapeutic implications - Institution: Institute of Traditional Chinese Medicine Health Industry, China Academy of Chinese Medical Sciences (with co-authors from Tianjin Medical University General Hospital and Tianjin First Central Hospital)
- Country: China
- Journal: Mechanisms of Ageing and Development (Elsevier), Volume 231, 2026, article 112174
-
Impact Evaluation: The journal’s 2024 Journal Impact Factor is approximately 4.0–5.0 (reported as ~4.95), with a CiteScore of 7.9 and a Q1 SCImago ranking in aging/geriatrics.
The impact score of this journal is ~4.95 JIF (CiteScore 7.9), therefore this is a Medium impact journal